Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer

MT Newswires Live
03-06

Conduit Pharmaceuticals (CDT) said Thursday that a Nasdaq hearing panel granted it an extension to meet listing requirements, with plans to transfer its shares to the Nasdaq Capital Market.

The company said it must submit an application for the transfer by March 12 and meet all Nasdaq listing standards by March 31.

Conduit said it had been at risk of delisting for not meeting requirements related to minimum bid price, market value of publicly held shares, and market value of listed securities. It regained compliance with the minimum bid price rule as of Feb. 26, according to the company.

Following the transfer, the company expects to meet the continued listing requirement for publicly held shares above $1.0 million and believes it will satisfy the Nasdaq equity standard of stockholder's equity above $2.5 million before the March 31 deadline, though it cautioned that compliance is not assured.

Shares of Conduit Pharmaceuticals were up nearly 4% in recent trading.

Price: 1.11, Change: +0.04, Percent Change: +3.74

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10